Advertisement
U.S. Markets closed

Ind-Swift Laboratories Limited (INDSWFTLAB.BO)

BSE - BSE Real Time Price. Currency in INR
121.55-2.45 (-1.98%)
At close: 03:15PM IST

Ind-Swift Laboratories Limited

Shivalik Enclave
SCO 850 NAC
Manimajra 160101
India
91 17 2506 1850
https://www.indswiftlabs.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees47

Key Executives

NameTitlePayExercisedYear Born
Mr. Navrattan R. MunjalChairman & MD30.31MN/A1952
Mr. Himanshu Jain BComJoint MD & Whole Time Director37.88MN/A1982
Mr. Rishav MehtaExecutive Director15.16MN/A1991
Mr. Sahil MunjalPresident of Operations & Special Assignments and Executive Director17.91MN/A1980
Mr. Gagan AggarwalChief Financial OfficerN/AN/AN/A
Ashok KothariGeneral Manager of Information & TechnologyN/AN/AN/A
Mr. Pardeep VermaVP of Corporate Affairs, Compliance Officer & Company SecretaryN/AN/AN/A
Varun ChhabraSenior Vice President of MarketingN/AN/AN/A
Akashdeep SharmaGroup HR HeadN/AN/AN/A
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is headquartered in Manimajra, India.

Corporate Governance

Ind-Swift Laboratories Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.